Physician profile
Mariah Danielle Wagoner
NPI 1811528037
$3,208.11
in general payments reported to CMS, 2019-2025
25 companies · $48.21 in 2025
The $48.21 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $767 · 2022: $744 · 2023: $1,256 · 2024: $394 · 2025: $48.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $679.54 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $366.16 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $285.81 | 2021-2023 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $223.82 | 2022-2023 | |
| Novo Nordisk INC | $222.05 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $211.12 | 2021-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $209.97 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.84 | 2023-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $147.54 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $111.81 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.38 | 2022 | |
| Amgen INC. | $64.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $63.95 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $61.81 | 2023 | Gemtesa |
| Almatica Pharma LLC | $46.48 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.44 | 2022-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $32.69 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $29.13 | 2022 | |
| Eisai INC. | $24.45 | 2024 | |
| Esperion Therapeutics, INC. | $20.08 | 2023 | Nexletol |
| Exact Sciences Corporation | $18.52 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $15.72 | 2024 | Watchman Flx |
| Amarin Pharma, INC. | $14.81 | 2021 | |
| Lundbeck LLC | $14.27 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $14.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariah Wagoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.